The Nasdaq-listed biotech plans to use proceeds for HCW9302 clinical trials and development work on HCW11-018b and HCW11-040, while investor warrants remain subject to stockholder approval under Nasdaq rules.
verifying reliability
No specialized terms available for this topic.